ABIONYX Pharma Settles Bond Amortization with Share Issuance

ABIONYX Pharma has announced the partial repayment of bond principal subscribed by Fenja Capital. The company settled EUR 1.75 million in principal, with a significant portion managed through the issuance of 331,299 new ordinary shares to Fenja. This shares issuance amounted to EUR 0.52 million, priced at EUR 1.58103 per share. This approach allowed ABIONYX to address its financing obligations without impacting its cash runway, which remains secure until Q4 2028.

The issuance occurred under the 21st resolution of the General Meeting, ensuring that preferential subscription rights were canceled, and was implemented by the company's board. Relevant New Shares will be tradable on Euronext Paris from October 6, 2026. Despite dilution, the financial strategy does not alter ABIONYX's capital structure significantly.